Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (June 2022)

41 slides from Centessa Pharmaceuticals's investor presentation, Jun 2, 2022

  1. Slide 1: Corporate Overview June 2022

    Corporate Overview JUNE 2022

  2. Slide 2: Disclaimer and forward-looking statements

    This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv

  3. Slide 3: R&D innovation engine to deliver impactful medicines to patients

    3 We are an R&D innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients

  4. Slide 4: Centessa management team with deep R&D experience

    Centessa management team with deep R&D experience 4 MARELLA THORELL Chief Accounting Officer THOMAS TEMPLEMAN PhD Chief Technology Officer DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Deve

  5. Slide 5: Portfolio of rare disease and immuno-oncology programs

    5 Portfolio of rare disease and immuno- oncology programs targeting multi-billion dollar markets SerpinPC in Hemophilia (Hemophilia B for initial registrational trial) REGISTRATIONAL (Programs in registrational trials this year) LB101 and LB201 in Solid Tumors ZF874 in Alpha-1 Antitrypsin Deficiency

  6. Slide 6: Asset, disease, reason to believe, market validation

    Asset Disease Reason to believe Market validation SerpinPC Hemophilia A and B Associated with promising ABR reduction and infrequent subcutaneous dosing with limited risk of thrombosis $2B+ licensing deal in 2020 for Hemophilia B gene therapy in Phase 3 clinical trials LB101 / LB201 Solid Tumors Pla

  7. Slide 7: Upcoming 2022 catalysts with cash runway into 2026

    Upcoming 2022 catalysts with cash runway now into 2026 $544.5 million cash and cash equivalents as of March 31, 2022 Note: On June 2, 2022, the Company updated its cash runway estimate following its strategic decision to voluntarily discontinue development of lixivaptan. Cash runway does not include

  8. Slide 8: SerpinPC in Hemophilia

    SerpinPC in Hemophilia 8

  9. Slide 9: SerpinPC potential to shift Hemophilia B treatment paradigm

    SerpinPC has the potential to shift Hemophilia B treatment paradigm 9 • Human genetic target validation in individuals who co-inherit Factor V Leiden mutation and either FVIII or FIX mutations reinforced with positive proof-of-concept Phase 2 data GENETIC VALIDATION AND CLINICAL PROOF OF CONCEPT FOR

  10. Slide 10: SerpinPC unique MoA supported by human genetics

    SerpinPC is believed to have a unique MoA supported by human genetics 10 Extrinsic Tenase Intrinsic Tenase Prothrombinase Prothrombin Thrombin SerpinPC APC Protein C Feedback Loop SerpinPC reduces levels of circulating APC (1), thereby prolonging activity of prothrombinase (2) and directly increasin

  11. Slide 11: SerpinPC reductions in bleeding rates in Phase 2a

    SerpinPC showed promising reductions in bleeding rates and was observed to be well-tolerated in the Phase 2a study Across all dose levels: • No thrombosis • No instances of sustained elevations in D-dimer • 1 moderate skin reaction led to withdrawal of a subject with history of a skin disorder • Two

  12. Slide 12: Two registrational trials planned in Hemophilia B

    Two registrational trials planned to start in 2H 2022 in Hemophilia B Hem B without inhibitors Part 1 Randomized dose-justification (24 weeks on treatment, n = 60) Observation period SerpinPC Multiple cohorts with different dosing frequency Hem B without inhibitors Part 2 Expansion phase at selected

  13. Slide 13: LB101 & LB201 in Solid Tumors

    13 LB101 & LB201 in Solid Tumors

  14. Slide 14: LockBody platform to redefine tumor-specific cell killing

    LockBody® platform aims to redefine tumor-specific cell killing 14 • LockBody® mechanism aims to bypass “sink” effects, minimize peripheral toxicity, and enable tumor- localized effector function activity of contingent domains, such as CD47 or CD3, directly into the tumor PLATFORM DESIGNED TO ADDRES

  15. Slide 15: Unique, modular platform for multiple LockBody permutations

    15 Confidential Unique, modular platform for multiple LockBody® permutations Constitutive Fab options for targets expressed in diseased tissues Hinge options with tunable rates of cleavage Contingent Fab options for tumor cell or immune cell engager targets Fc region variations for further modulatio

  16. Slide 16: LB101 provides anti-PD-L1 plus CD47-targeted activity in the TME

    16 Constitutive Fabs: PD-L1 Domains Fully human Contingent Fabs: Locked CD47 Domains Natural cleavage of IgG-derived hinges in tumors IgG1 Fc Exposed CDRs Locked Unlocked LB101 is designed to provide anti-PD-L1 activity plus CD47-targeted activity in the TME

  17. Slide 17: LockBody mechanism uses IgG-derived hinges susceptible to proteases

    LockBody® mechanism uses human IgG-derived hinges susceptible to multiple proteases in the TME 17 Jordan et al. “Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy” Oncoimmunology 2018 -D-K-T-H-T-C-P-P-C-P-A-P-E-L-L-G-G- Plasmin HNE Papain MMP-3, MMP-12 GluV8, Cathepsin G Pepsin

  18. Slide 18: In vitro: LB101 target binding in locked and unlocked states

    In vitro: LB101 demonstrated expected target binding in locked and unlocked states 18 LB101 binding to PD-L1 in the locked form, with CD47 binding after activation in the unlocked form Anti-PD-L1 potency similar to atezolizumab in locked form, and strongly enhanced ADCP in unlocked form Unlocked: CD

  19. Slide 19: In vivo: LB101 improved efficacy and durability

    In vivo: LB101 showed improved efficacy and durability over control and atezolizumab in a difficult-to-treat mouse model and was well tolerated Single-agent LB101 delivered systemically resulted in PD-L1 directed, local tumor-specific CD47 effector engagement leading to significant tumor regressions

  20. Slide 20: In vivo: systemic LB101 significant tumor regression

    In vivo: Systemically delivered LB101 exhibited significant tumor regression 20 Note: Arrows indicate dosing every 3 days (Q3d x 6) at Days 0, 3, 6, 9, 12, and 15. 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. 3000 2000 1000 0 0 Study Day IgG1 isotype control Atezolizumab 5 mg/kg Atez

  21. Slide 21: In vivo: LB101 higher survival, no growth in rechallenge

    In vivo: LB101 led to higher survival and showed no tumor growth in rechallenge experiment 21 Note: Arrows indicate dosing every 3 days (Q3d x 6) at Days 0, 3, 6, 9, 12, and 15. 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. Higher survival in mice treated with LB101 compared to isotyp

  22. Slide 22: In vivo: LB101 well tolerated with no weight loss

    In vivo: LB101 was well tolerated with no weight loss 22 40.0 35.0 30.0 25.0 15.0 10.0 5.0 0.0 0 Study Days IgG1 Isotype, 10mg/kg, 10 μl/g, i.p. Atezolizumab, 5mg/kg, 10 μl/g, i.p. Atezolizumab, 10mg/kg, 10 μl/g, i.p. LB101, 8.5mg/kg, 10 μl/g, i.p. LB101, 17 mg/kg, 10 μL/g, i.p. 10 20 40 50 M e a n

  23. Slide 23: LockBody development plan and upcoming milestones

    LockBody® development plan and upcoming milestones 23 Planning to submit an IND for LB101 (PD-L1xCD47 LockBody®) in late 2022 Planning to submit an IND for LB201 (PD-L1xCD3 LockBody®) in 2023 Continuing to explore full potential of the technology in improving the therapeutic index of other anticance

  24. Slide 24: ZF874 in AATD

    ZF874 in AATD 24

  25. Slide 25: ZF874 potential disease-modifying treatment for AATD

    ZF874 has the potential to be a disease-modifying treatment for AATD 25 • ZF874 is designed to bind to the stalled folding intermediate specific to Z-A1AT with no detectable binding to fully folded Z-A1AT in vitro; ZF887 in preclin. development, structurally unrelated to ZF874 DESIGNED AS A CATALYTI

  26. Slide 26: Low doses of ZF874 clear polymer and reduce fibrosis

    26 ZF874-treated 54 mpk/day (HED 7 mpk/day) Vehicle Z-A1AT polymer (PAS-D staining) Fibrosis (Sirius Red staining) Liver histology from 84-day treatment of mice expressing human Z-A1AT (PiZ mice) Abbreviations: mpk = milligrams per kilogram; PAS-D = Periodic Acid-Schiff staining with diastase; HED =

  27. Slide 27: Clinical data in PiMZ subjects dosed with placebo or ZF874

    Clinical data in PiMZ subjects dosed with placebo or ZF874 15 mpk BID 27 * Activity level equivalent to molar amount of M A1AT reference standard. Baseline for each subject = average of Pre-Screen , Day -1, and Day 1 Pre-Dose values for each subject † Trapezoidal AUC for the first 12 hours after the

  28. Slide 28: Liver signal in one PiMZ subject with highest exposure

    Liver signal in one PiMZ subject with highest exposure in Part B 0 100 200 300 400 500 600 700 -21 -14 -7 0 7 14 21 28 35 42 49 56 63 70 28 ALT (IU/L) Time after 1st dose (days) Treatment period ULN ♂ (70 IU/L) Subject 2002 ♂ Placebo Subject 2003 ♀ AUC0-12hr 181 µg·hr/ml Subject 2001 ♂ AUC0-12hr 350

  29. Slide 29: Overview of ongoing Phase 1 trial of ZF874 in AATD

    Overview of ongoing Phase 1 trial of ZF874 in AATD 1. Morning doses given in the fasted state. Evening doses given after an evening meal Note: 2 subjects received placebo in each cohort for Cohorts 1-6 and none in Cohort 7 15 mg/kg, fed Part A, Cohort 7 (n=6)25 mg/kg BID(1) Part A, Cohort 6 (n=8) 15

  30. Slide 30: MGX292 in PAH

    MGX292 in PAH 30

  31. Slide 31: MGX292 potential for disease reversal in PAH

    MGX292 has the potential for disease reversal / modification in PAH 31 • Recombinant modified BMP9 replacement protein designed to directly target BMPR2/ALK1 pathway vs. experimental therapies which inhibit Activin signaling with only indirect effects on this pathway DESIGNED TO DIRECTLY TARGET CENT

  32. Slide 32: MGX292 directly targets central underlying disease mechanism

    MGX292 is designed to directly target central underlying disease mechanism 32 In PAH, reduced BMP9 signaling results in the pathological changes underlying PAH. With MGX292 treatment, supplementation with exogenous recombinant BMP9 protein (MGX292) leads to restored signaling and normalization of en

  33. Slide 33: MGX292 dose-dependent reversal of lung vascular pathology

    MGX292 demonstrated dose-dependent reversal of established lung vascular pathology in Sugen-hypoxia rat model MGX2921 reversed neointimal lesions in Sugen-hypoxia rat model of severe PAH 0 5 10 15 20 Normoxic vehicle 3 weeks vehicle 7 weeks vehicle BMP9 (10µg/kg) MGX292 (3µg/kg) MGX292 (10µg/kg) MGX

  34. Slide 34: Development plan for MGX292 in PAH

    Development plan for MGX292 in PAH Preclinical development ongoing, currently in the IND-enabling stage Plan to conduct pre-IND meeting with the FDA in the second half of 2022 Plan to submit an IND for MGX292 in early 2023 34

  35. Slide 35: OX2R Agonists in NT1

    35 OX2R Agonists in NT1

  36. Slide 36: Orexin agonists potential to change standard of care in narcolepsy

    Our novel orexin agonist approaches have the potential to change the global standard of care in narcolepsy 36 • Lead molecules are designed to selectively target the Orexin Receptor-2 (OX2R) based on structure- based drug design DESIGNED TO DIRECTLY TARGET UNDERLYING PATHOPHYSIOLOGY OF DISEASE • Obs

  37. Slide 37: Small molecule and peptide orexin agonists replacement therapy

    Our small molecule and peptide orexin agonists are designed to provide a potential replacement therapy approach in NT1 37 Example X-ray structure of OX2R with small molecule orexin agonist (shown in purple) Example Cryo-EM structure of OX2R with peptide agonist (shown in purple) Our small molecule a

  38. Slide 38: Orexin agonists increase wakefulness in mice

    Novel small molecule and peptide orexin agonists demonstrated dose- dependent effects in increasing wakefulness in mice Exemplar small molecule agonists Exemplar peptide agonist Wakefulness detected by piezoelectric monitoring, which is a rapid, non-invasive method for classifying sleep and wakefuln

  39. Slide 39: Development plan for orexin agonists in NT1

    Development plan for orexin agonists in NT1 Plan to submit IND / CTA for lead oral program in 2023 Plan to submit IND / CTA for intranasal program in 2023 Intend to explore additional indications beyond NT1 39

  40. Slide 40: Key value drivers

    Key value drivers 40 Note: Cash runway does not include the remaining available tranches under the Oberland facility Substantial innovative pipeline of rare disease and immuno -oncology assets targeting multi-billion dollar markets Potential for multiple clinical proof of concept (PoC) readouts over

  41. Slide 41: Centessa Pharmaceuticals

    x CENTESSA PHARMACEUTICALS

Centessa Pharmaceuticals — Investor Presentation (June 2022) on 6ix